Skip to Main Content

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Conditions

Diseases of the Endocrine System

Phase II

What is the purpose of this trial?

Brief Summary:

This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 12-week, safety, efficacy, and systemic exposure study followed by a 12-week open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale

  • Trial with
    Mayne Pharma
  • Start Date
    11/21/2019
  • End Date
    09/09/2020
Trial Image

For more information about this study, contact:

Mahin Dawood

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/22/2020
  • Study HIC
    #2000024766